PUBLICATIONS

Read our peer reviewed and published expert content covering AustinPx's science and manufacturing technology.

Publications

2023

Thompson, S.A., Davis, D.A.,  Miller, D.A.,  Kucera, S.U., Williams, R.O. Biomedicines | Free Full-Text | Pre-Processing a Polymer Blend into a Polymer Alloy by KinetiSol Enables Increased Ivacaftor Amorphous Solid Dispersion Drug Loading and Dissolution (mdpi.com). Biomedicines (2023).

Thompson, S.A., Gala, U., Davis, D.A. et al. Can the Oral Bioavailability of the Discontinued Prostate Cancer Drug Galeterone Be Improved by Processing Method? KinetiSol™ Outperforms Spray Drying in a Head-to-head Comparison. AAPS PharmSciTech 24, 137 (2023).

Corum, Isaac, Angela Spangenberg, Krystal Miller, Sandra U. Kucera, Dave A. Miller. Minimization of Acid-Catalyzed Degradation in KinetiSol™ Processing through HPMCAS Neutralization. Molecular Pharmaceutics. In Press.

2022

Davis Jr., Daniel A., Rishi Thakkar, Mohammed Maniruzzaman, Dave A. Miller, Robert O. Williams III. Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs. Formulating Poorly Water-Soluble Drugs, 599-650.

2021

Davis Jr, Daniel A., Dave A. Miller, Supawan Santitewagun, J. Axel Zeitler, Yongchao Su, Robert O. Williams III. Formulating a heat-and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity. International journal of pharmaceutics: X, Vol. 3, 100092 (2021).

Gala, Urvi H., Dave A. Miller, Yongchao Su, Angela Spangenberg, Robert O. Williams III. “The effect of drug loading on the properties of abiraterone–hydroxypropyl beta cyclodextrin solid dispersions processed by solvent free KinetiSol™ technology. European Journal of Pharmaceutics and Biopharmaceutics 165, 52-65 (2021).

2020

Davis, Daniel A., Dave A. Miller, Yongchao Su, Robert O. Williams III. Thermally conductive excipient expands kinetiSol™ processing capabilities. AAPS PharmSciTech 21 (8), 1-15

Deck Khong Tan, Davis, Daniel A., Miller, Dave A., Williams, Robert O., Nokhodchi, Ali. Innovations in thermal processing: hot-melt extrusion and KinetiSol™ dispersing. AAPS PharmSciTech 21, 312 (2020). https://doi.org/10.1208/s12249-020-01854-2.

Jermain, Scott V., Michael B. Lowinger, Daniel J. Ellenberger, Dave A. Miller, Yongchao Su,and Robert O. Williams, III. In Vitro and In Vivo Behaviors of KinetiSol™ and Spray-Dried Amorphous Solid Dispersions of a Weakly Basic Drug and Ionic Polymer. Mol. Pharmaceutics 2020, 17, 2789−2808.

Gala, Urvi H., Dave A. Miller, and Robert O. Williams III. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. BBA - Reviews on Cancer 1873 (2020).

Gala, Urvi H., Dave A. Miller, and Robert O. Williams III. Improved Dissolution and Pharmacokinetics of Abiraterone through KinetiSol™ Enabled Amorphous Solid Dispersions. Pharmaceutics 2020, 12(4), 357; https://doi.org/10.3390/pharmaceutics12040357

 2019

Jermain, Scott V., Dave A. Miller, Angela Spangenberg,  Xingyu Lu, Chaeho Moon, Yongchao Su, Robert O. Williams III. “Homogeneity of amorphous solid dispersions – an example with KinetiSol™ ” Drug Development and Industrial Pharmacy, DOI. Epub 2019 January 25.

2018

Ellenberger, D.J., Dave A. Miller, Sandra U. Kucera, Robert O. Williams III. “Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet.” AAPS PharmSciTech. 2018 June; Epub ahead of print.

Ellenberger, D.J., Dave A. Miller, Robert O. Williams III. “Expanding the Application and Formulation Space of Amorphous Solid Dispersions with KinetiSol™: a Review AAPS PharmSciTech. Epub 2018 May 30.

Ellenberger, D.J., Dave A. Miller, Sandra U. Kucera, Robert O. Williams III. “Improved Vemurafenib Dissolution and Pharmacokinetics as an Amorphous Solid Dispersion Produced by KinetiSol™ Processing.” AAPS PharmSciTech. 2018 Mar; Epub ahead of print.

2017

Keen, J.M., Justin S. LaFountaine, Justin R. Hughey, Dave A. Miller, James W. McGinity. Development of Itraconazole Tablets Containing Viscous KinetiSol™ Solid Dispersions: In Vitro and In Vivo Analysis in Dogs.” AAPS PharmSciTech. 2017 Nov;  doi: 10.1208/s12249-017-0903-1. [Epub ahead of print].

Keen, J.M.,  Dave A. Miller and Simon Tulloch. “Phase I Trial Results of a Solid Dispersion Formulation of Deferasirox with Enhanced Bioavailability Relative to Exjade® and Jadenu™. Blood. 2017; 130:2215.

LaFountaine, J.S., Leena Kumari Prasad, Dave A. Miller, James W. McGinity, Robert O.Williams III. “Mucoadhesive Amorphous Solid Dispersions for Sustained Release of Poorly Water Soluble Drugs.European Journal of Pharmaceutics and Biopharmaceutics. 2017 Apr; 113:157-167. doi: 10.1016/j.ejpb.2016.12.031. Epub 2017 Jan 11.

 

 

2016

LaFountaine, J.S.,  Scott V. Jermain, Leena Kumari Prasad, Chris Brough, Dave A. Miller, Dieter Lubda, James W. McGinity, Robert O. Williams III. “Enabling Thermal Processing of Ritonavir-Polyvinyl Alcohol Amorphous Solid Dispersions by KinetiSol™ Dispersing.” European Journal of Pharmaceutics and Biopharmaceutics. 2016 Apr; 101:72-81. doi: 10.1016/j.ejpb.2016.01.018. Epub 2016 Feb 6.

LaFountaine, Justin S., Leena K. Prasad, Chris Brough, Dave A. Miller, James W. McGinity, Robert O. Williams III. “Thermal Processing of PVP- and HPMC-based Amorphous Solid Dispersions.AAPS PharmSciTech. 2016 Feb; 17(1): 120–132.

2015

Brough, Chris, Dave A. Miller, Justin M. Keen, Shawn A. Kucera, Dieter Lubda, Robert O. Williams III. “New Use of Polyvinyl Alcohol as a Solubility Enhancing Polymer for Poorly Water-soluble Drug Delivery (Part 1).” AAPS PharmSciTech. 2016 Feb;17(1):167-79. doi: 10.1208/s12249-015-0458-y. Epub 2015 Dec 4.

LaFountaine, J.S., James W. McGinity, Robert O. Williams III. “Challenges and Strategies in Thermal Processing of Amorphous Solid Dispersions: A Review.” AAPS PharmSciTech. 2016 Feb; 17(1):43–55. doi: 10.1208/s12249-015-0393-y. Epub 2015 Aug 26.

Miller, Dave A., Justin M. Keen, Chris Brough, Daniel J. Ellenberger, Marshall Cisneros, Robert O. Williams III, James W. McGinity. “Bioavailability Enhancement of a BCS IV Compound Via an Amorphous Combination Product Containing Ritonavir.” Journal of Pharmacy and Pharmacology.  2016 May;68(5):678-91. doi: 10.1111/jphp.12478. Epub 2015 Oct 10.

2014

Miller, Dave A. and Justin M. Keen. KinetiSol-Based Amorphous Solid Dispersions. In: Amorphous Solid Dispersions, Editors: N. Shah, D. Choi, H. Sandhu, H. Chokshi, and W. Malick. Controlled Release Society and Springer Science. New York, NY, USA. In press, (2014).

2013

Bennett, R.C., Chris Brough, Dave A. Miller, K.P. O’Donnell, Justin M. Keen, Justin R. Hughey, Robert O. Williams III, and James W. McGinity. “Preparation of Amorphous Solid Dispersions by Rotary Evaporation and KinetiSol™ Dispersing: Approaches to Enhance Solubility of a Poorly Water-Soluble Gum Extract.Drug Development and Industrial Pharmacy: 1-16 (2013).

Keen, Justin M., James W. McGinity, and Robert O. Williams III. “Enhancing Bioavailability through Thermal Processing.International Journal of Pharmaceutics. vol. 450, pp. 185-196 (2013).

Brough, Chris and Robert O. Williams III. “Amorphous Solid Dispersions and Nano-Crystal Technologies for Poorly Water-Soluble drug delivery.International Journal of Pharmaceutics. vol. 453, pp. 157-166 (2013).

2012

McGinity, James W., Robert O. Williams III, Justin R. Hughey, James C. DiNunzio, and Dave A. Miller. KinetiSol™: A Novel Process for the Production of Pharmaceutical Solid Dispersion Systems.Bulletin Technique Gattefosse. no. 105 (2012): 68-78.

Miller, Dave A., James C. DiNunzio, Justin R. Hughey, Robert O. Williams III, and James W. McGinity. KinetiSol™: A New Processing Paradigm for Amorphous Solid Dispersion Systems.” Drug Development & Delivery. vol. 12, no. 9, November/December (2012).

Hughey, Justin R., Justin M. Keen, Dave A. Miller, Chris Brough, and James W. McGinity. Preparation and Characterization of Fusion Processed Solid Dispersions Containing a Viscous Thermally Labile Polymeric Carrier.” International Journal of Pharmaceutics. vol. 438 (2012): 11 – 19.

2011

Hughey, Justin R., Justin M. Keen, Chris Brough, Sophie Saeger, and James W. McGinity. Thermal Processing of a Poorly Water- Soluble Drug Substance Exhibiting a High Melting Point: The Utility of KinetiSol™ Dispersing.” International Journal of Pharmaceutics. vol. 419, no. 1–2 (2011): 222-230.

2010

Hughey, Justin R., James C. DiNunzio, Ryan C. Bennett, Chris Brough, Dave A. Miller, Hua Ma, Robert O. Williams III, and James W. McGinity. Dissolution Enhancement of a Drug Exhibiting Thermal and Acidic Decomposition Characteristics by Fusion Processing: A Comparative Study of Hot Melt Extrusion and KinetiSol™ Dispersing.” AAPS PharmSciTech. vol. 11, no. 2 (2010): 760-774.

DiNunzio, James C., Justin R. Hughey, Chris Brough, Dave A. Miller, Robert O. Williams III, and James W. McGinity. Production of Advanced Solid Dispersions for Enhanced Bioavailability of Itraconazole Using KinetiSol™ Dispersing.Drug Development and Industrial Pharmacy. vol. 36, no. 9 (2010): 1064-1078.

DiNunzio, James C., Chris Brough, Dave A. Miller, Robert O. Williams III, and James W. McGinity. Fusion Processing of Itraconazole Solid Dispersions by KinetiSol™ Dispersing: A Comparative Study to Hot Melt Extrusion.Journal of Pharmaceutical Sciences. vol. 99, no. 3 (2010): 1239-1253.

DiNunzio, James C., Chris Brough, Dave A. Miller, Robert O. Williams III, and James W. McGinity. Applications of KinetiSol™ Dispersing for the Production of Plasticizer Free Amorphous Solid Dispersions.European Journal of Pharmaceutical Sciences. vol. 40, no. 3 (2010): 179-187.

DiNunzio, James C., Chris Brough, Justin R. Hughey, Dave A. Miller, Robert O. Williams III, and James W. McGinity. Fusion Production of Solid Dispersions Containing a Heat-Sensitive Active Ingredient by Hot Melt Extrusion and KinetiSol™ Dispersing.” European Journal of Pharmaceutics and Biopharmaceutics. vol. 74, no. 2 (2010): 340-351.